Marker Therapeutics Q3 net loss narrows to $2 mln

Marker Therapeutics

14/11/2025 12:10

Overview

Marker Q3 net loss narrows to $2 mln from $2.3 mln yr/yr

MT-601 shows 66% response rate in relapsed NHL patients

Company raises $10 mln through ATM facility, extending cash runway into 2026

Outlook

Marker plans to share additional MT-601 data in the first half of 2026

Company focuses on enrolling patients in MT-601 dose expansion cohort

Marker's cash runway extended into 2026 through recent fundraising

Result Drivers

R&D - Expenses were $2.3 million for the quarter ended September 30, 2025, compared to $3.5 million for the quarter ended September 30, 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.12


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Marker Therapeutics Inc is $8.00, about 88.9% above its November 13 closing price of $0.89

Press Release: ID:nGNXf0BNb

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)